Management of mantle cell lymphoma in the elderly patient

References

• SwerdlowSHCampoEHarrisNLWHO Classification of Tumours of Haematopoietic and Lymphoid TissuesLyonIARC2008
   Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphomaThe Non-Hodgkin’s Lymphoma Classification ProjectBlood19978911390939189166827
   PubMed Web of Science ®Google Scholar
• HerrmannAHosterEZwingersTImprovement of overall survival in advanced stage mantle cell lymphomaJ Clin Oncol200927451151819075279
   PubMed Web of Science ®Google Scholar
• FuKWeisenburgerDDGreinerTCCyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profilingBlood2005106134315432116123218
   PubMed Web of Science ®Google Scholar
• RomagueraJEMedeirosLJHagemeisterFBFrequency of gastrointestinal involvement and its clinical significance in mantle cell lymphomaCancer200397358659112548600
   PubMed Web of Science ®Google Scholar
• FerrerASalaverriaIBoschFLeukemic involvement is a common feature in mantle cell lymphomaCancer2007109122473248017477385
   PubMed Web of Science ®Google Scholar
• FerrerABoschFVillamorNCentral nervous system involvement in mantle cell lymphomaAnn Oncol200819113514117962207
   PubMed Web of Science ®Google Scholar
• GillSHerbertKEPrinceHMMantle cell lymphoma with central nervous system involvement: frequency and clinical featuresBr J Haematol20091471838819694718
   PubMed Web of Science ®Google Scholar
• ConconiAFranceschettiSLobetti-BodoniCRisk factors of central nervous system relapse in mantle cell lymphomaLeuk Lymphoma Epub2202013
   Web of Science ®Google Scholar
• ChesonBDPfistnerBJuweidMERevised response criteria for malignant lymphomaJ Clin Oncol200725557958617242396
   PubMed Web of Science ®Google Scholar
• HoseinPJPastoriniVHPaesFMUtility of positron emission tomography scans in mantle cell lymphomaAm J Hematol2011861084184521922524
   PubMed Web of Science ®Google Scholar
• CarbonePPKaplanHSMusshoffKSmithersDWTubianaMReport of the committee on Hodgkin’s disease staging classificationCancer Res19713111186018615121694
   PubMed Web of Science ®Google Scholar
• OrchardJGarandRDavisZA subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal diseaseBlood2003101124975498112609845
   PubMed Web of Science ®Google Scholar
• HosterEDreylingMKlapperWA new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood2008111255856517962512
   PubMed Web of Science ®Google Scholar
• DetermannOHosterEOttGKi-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study GroupBlood200811142385238718077791
   PubMed Web of Science ®Google Scholar
• KlapperWHosterEDetermannOKi-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL NetworkJ Hematop20092210311119669190
   PubMedGoogle Scholar
• HowardOMGribbenJGNeubergDSRituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survivalJ Clin Oncol20022051288129411870171
   PubMed Web of Science ®Google Scholar
• LenzGDreylingMHosterEImmunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)J Clin Oncol20052391984199215668467
   PubMed Web of Science ®Google Scholar
• SchulzHBohliusJFTrelleSImmunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysisJ Natl Cancer Inst200799970671417470738
   PubMed Web of Science ®Google Scholar
• GriffithsRMikhaelJGleesonMDaneseMDreylingMAddition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphomaBlood2011118184808481621873544
   PubMed Web of Science ®Google Scholar
• KhouriIFRomagueraJKantarjianHHyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphomaJ Clin Oncol19981612380338099850025
   PubMed Web of Science ®Google Scholar
• van ‘t VeerMBde JongDMacKenzieMHigh-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patientsBr J Haematol2009144452453019036081
   PubMed Web of Science ®Google Scholar
• GeislerCHKolstadALaurellANordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occurBr J Haematol2012158335536222640180
   PubMed Web of Science ®Google Scholar
• DelarueRHaiounCRibragVCHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’AdulteBlood20131211485322718839
   PubMed Web of Science ®Google Scholar
• DreylingMLenzGHosterEEarly consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL NetworkBlood200510572677268415591112
   PubMed Web of Science ®Google Scholar
• VandenbergheERuiz de ElviraCLoberizaFROutcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant RegistriesBr J Haematol2003120579380012614212
   PubMed Web of Science ®Google Scholar
• PeterlinPLeuxCGastinneTIs ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?Transplantation201294329530122797728
   PubMed Web of Science ®Google Scholar
• LeitchHAGascoyneRDChhanabhaiMVossNJKlasaRConnorsJMLimited-stage mantle-cell lymphomaAnn Oncol200314101555156114504058
   PubMed Web of Science ®Google Scholar
• BernardMTsangRWLeLWLimited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret HospitalLeuk Lymphoma201354226126722793378
   PubMed Web of Science ®Google Scholar
• PottCHosterEDelfau-LarueMHMolecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyBlood2010115163215322320032498
   PubMed Web of Science ®Google Scholar
• Kluin-NelemansHCHosterEHermineOTreatment of older patients with mantle-cell lymphomaN Engl J Med2012367652053122873532
   PubMed Web of Science ®Google Scholar
• RummelMJNiederleNMaschmeyerGBendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet201338198731203121023433739
   PubMed Web of Science ®Google Scholar
• BauwensDMaerevoetMMichauxLActivity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphomaBr J Haematol2005131333834016225653
   PubMed Web of Science ®Google Scholar
• GhielminiMSchmitzSFCogliattiSEffect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)J Clin Oncol200523470571115598978
   PubMed Web of Science ®Google Scholar
• RosenbluthBDYahalomJHighly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)Int J Radiat Oncol Biol Phys20066541185119116682133
   PubMed Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphomaJ Clin Oncol200523153383338915908650
   PubMed Web of Science ®Google Scholar
• WeideRFeitenSFriesenhahnVRetreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissionsLeuk Lymphoma Epub1252012
   Web of Science ®Google Scholar
• WeideRHessGKopplerHHigh anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Leuk Lymphoma20074871299130617613757
   PubMed Web of Science ®Google Scholar
• ThomasDWOwenRGJohnsonSASuperior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOPLeuk Lymphoma200546454955216019483
   PubMed Web of Science ®Google Scholar
• ForstpointnerRDreylingMReppRThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2004104103064307115284112
   PubMed Web of Science ®Google Scholar
• ForstpointnerRUnterhaltMDreylingMMaintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Blood2006108134003400816946304
   PubMed Web of Science ®Google Scholar
• ViscoCFinottoSZambelloRCombination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantationJ Clin Oncol201331111442144923401442
   PubMed Web of Science ®Google Scholar
• InwardsDJFishkinPAHillmanDWLong-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment GroupCancer2008113110811618470909
   PubMed Web of Science ®Google Scholar
• FisherRIBernsteinSHKahlBSMulticenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaJ Clin Oncol200624304867487417001068
   PubMed Web of Science ®Google Scholar
• O’ConnorOAMoskowitzCPortlockCPatients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialBr J Haematol20091451343919220284
   PubMed Web of Science ®Google Scholar
• MoreauPPylypenkoHGrosickiSSubcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority studyLancet Oncol201112543144021507715
   PubMed Web of Science ®Google Scholar
• WeigertOWeidmannEMueckRA novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation studyLeuk Lymphoma200950571672219347767
   PubMed Web of Science ®Google Scholar
• WitzigTEGeyerSMGhobrialIPhase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphomaJ Clin Oncol200523235347535615983389
   PubMed Web of Science ®Google Scholar
• AnsellSMInwardsDJRowlandKMJrLow-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a Phase 2 trial in the North Central Cancer Treatment GroupCancer2008113350851418543327
   PubMed Web of Science ®Google Scholar
• HessGHerbrechtRRomagueraJPhase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphomaJ Clin Oncol200927233822382919581539
   PubMed Web of Science ®Google Scholar
• WitzigTEVoseJMZinzaniPLAn international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphomaAnn Oncol20112271622162721228334
   PubMed Web of Science ®Google Scholar
• HabermannTMLossosISJusticeGLenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaBr J Haematol2009145334434919245430
   PubMed Web of Science ®Google Scholar
• CookGSmithGMKirklandKOutcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow TransplantationBiol Blood Marrow Transplant201016101419142720399879
   PubMed Web of Science ®Google Scholar
• FriedbergJWSharmanJSweetenhamJInhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood2010115132578258519965662
   PubMed Web of Science ®Google Scholar
• MorschhauserFSeymourJFKluin-NelemansHCA Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphomaAnn Oncol200819224725317906297
   PubMed Web of Science ®Google Scholar
• BurgerJABuggyJJEmerging drug profiles: Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765)Leuk Lymphoma Epub2212013
   PubMed Web of Science ®Google Scholar
• AdvaniRHBuggyJJSharmanJPBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol2013311889423045577
   PubMed Web of Science ®Google Scholar
• WangMLRuleSMartinPTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaN Engl J Med Epub6192013
   Web of Science ®Google Scholar